Aurealis Therapeutics
Switzerland - ZugBiotechnology
Focus: Aurealis Therapeutics is a Swiss-based biotechnology company specializing in transdermal drug delivery technologies, founded in 1991 and currently in the public markets. The company has a highly focused pipeline centered on dermatological and wound care applications.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Aurealis Therapeutics?
AI assessmentCareer fit depends on whether you seek deep specialization in niche transdermal technology or prefer broader exposure; the minimal hiring and undisclosed financials suggest this is a turnaround or extremely capital-constrained play.
Why Work Here
- Established 30+ year history in transdermal technology provides deep domain expertise and specialized knowledge not available at most biotech firms
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AUP1602-C
Diabetic Foot UlcerClinical Trials (2)
NCT06111183Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)
Phase 2Help build intelligence for Aurealis Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.